宫颈癌治疗后高危型人乳头瘤病毒转阴与预后关系研究

发布时间：2018-03-22 15:03

本文选题：宫颈肿瘤　切入点：高危型人乳头瘤病毒　出处：《中国实用妇科与产科杂志》2017年09期 　论文类型：期刊论文

【摘要】：目的探讨宫颈癌患者治疗后高危型人乳头瘤病毒(HR-HPV)转阴情况与宫颈癌预后的关系。方法回顾性分析2011年1月至2012年12月在首都医科大学附属北京妇产医院接受治疗的宫颈癌患者189例,随访截止至2015年12月。观察宫颈癌复发及患者生存情况,并对其与HR-HPV转阴的关系进行研究。结果 189例宫颈癌患者中鳞癌173例,腺癌16例;接受治疗后,存活3年以上患者161例,3年内死亡28例;HR-HPV转阴152例,持续阳性37例;复发患者39例,其中盆腔复发22例,远处转移17例。宫颈癌治疗后HR-HPV是否转阴对宫颈癌复发及3年生存率均有明显统计学意义(P0.05)。HR-HPV是否转阴对盆腔复发有统计学意义(P0.05),而对远处转移无统计学意义(P0.05)。HR-HPV和细胞学检查对宫颈癌复发的灵敏度分别为72.97%和57.50%,差异有统计学意义(P=0.017);特异度分别为92.11%和89.26%,差异无统计学意义(P=0.318)。结论宫颈癌治疗后HR-HPV持续阳性增加复发及死亡危险;HR-HPV持续阳性增加局部复发的危险,但并不增加远处转移的危险;HR-HPV阴性也不能杜绝局部复发与远处转移;HR-HPV监测复发灵敏度及特异度均高于细胞学检查。宫颈癌治疗后进行HR-HPV监测可能是必要的。
[Abstract]:Objective to investigate the patients with cervical cancer after treatment of high-risk human papilloma virus (HR-HPV) negative relationship with the prognosis of cervical cancer. Methods a retrospective analysis from January 2011 to December 2012 treated in the Beijing Obstetrics and Gynecology Hospital affiliated to the Capital Medical University of cervical cancer 189 cases, follow-up cut-off to December 2015. Observation of cervical cancer recurrence and survival of patients, and the relationship with HR-HPV negative were studied. Results 189 cases of squamous cell carcinoma in patients with cervical cancer in 173 cases, 16 cases of adenocarcinoma; after the treatment, 161 cases survived more than 3 years with 3 years and 28 cases died in 152 cases; HR-HPV negative, continuous positive 37 cases; 39 cases of recurrent patients, including 22 cases of pelvic recurrence and distant 17 cases of metastatic cervical cancer. After the treatment of HR-HPV is negative for cervical cancer recurrence and 3 year survival rates were statistically significant (P0.05).HR-HPV negative was statistically significant for pelvic recurrence (P0.05), while the far Transfer was not statistically significant (P0.05) sensitivity of.HR-HPV and cytology for cervical cancer recurrence were 72.97% and 57.50%, the difference was statistically significant (P=0.017); the specificity was 92.11% and 89.26% respectively, the difference was not statistically significant (P=0.318). Conclusion the treatment of cervical cancer after HR-HPV continuous positive increase in recurrence and death risk; HR-HPV positive increase the risk of local recurrence, but did not increase the risk of distant metastasis; HR-HPV negative can not prevent local recurrence and distant metastasis; recurrence HR-HPV sensitivity and specificity were higher than that of cytology. The treatment of cervical cancer after HR-HPV monitoring may be necessary.

【作者单位】：首都医科大学附属北京妇产医院妇瘤科;
【基金】：北京市科委生物医药与生命科学创新培育研究项目(Z151100003915149)
【分类号】：R737.33

【相似文献】